Compare Stocks → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:DMTKNASDAQ:FENC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/ADMTKDermTech$0.62$0.66$0.57▼$3.90$21.63M2.53292,574 shs139,657 shsFENCFennec Pharmaceuticals$9.75+3.5%$10.07$6.30▼$11.92$266.34M0.45110,639 shs102,221 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%+0.00%+0.00%+0.00%DMTKDermTech-3.28%-1.49%-6.77%-50.40%-76.34%FENCFennec Pharmaceuticals+1.62%+3.63%-13.50%-7.28%+19.24%“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ADMTKDermTech0.4775 of 5 stars3.00.00.00.00.00.01.3FENCFennec Pharmaceuticals3.0042 of 5 stars3.51.00.00.02.82.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/ADMTKDermTech2.00Hold$2.38280.45% UpsideFENCFennec Pharmaceuticals3.00Buy$17.3377.78% UpsideCurrent Analyst RatingsLatest AYLA, FENC, and DMTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/19/2024DMTKDermTechLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$0.634/19/2024DMTKDermTechStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$1.504/19/2024DMTKDermTechBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.003/5/2024DMTKDermTechStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.50 ➝ $1.50(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21DMTKDermTech$15.30M1.41N/AN/A$1.67 per share0.37FENCFennec Pharmaceuticals$21.25M12.53N/AN/A($0.43) per share-22.67Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ADMTKDermTech-$100.89M-$3.14N/AN/AN/A-659.57%-123.96%-67.94%5/16/2024 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.93N/A-75.50%N/A-73.64%5/14/2024 (Confirmed)Latest AYLA, FENC, and DMTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024N/AFENCFennec Pharmaceuticals$0.49N/A-$0.49N/AN/AN/A 3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 million2/29/2024Q4 2023DMTKDermTech-$0.54-$0.56-$0.02-$0.56$4.05 million$3.92 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ADMTKDermTechN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28DMTKDermTechN/A4.594.52FENCFennec PharmaceuticalsN/A3.563.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%DMTKDermTech20.45%FENCFennec Pharmaceuticals55.51%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%DMTKDermTech5.10%FENCFennec Pharmaceuticals11.25%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableDMTKDermTech20634.62 million32.86 millionOptionableFENCFennec PharmaceuticalsN/A27.32 million24.24 millionOptionableAYLA, FENC, and DMTK HeadlinesSourceHeadlineFennec Pharmaceuticals (FENC) Scheduled to Post Quarterly Earnings on Tuesdaymarketbeat.com - May 8 at 10:17 AMFennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024globenewswire.com - May 7 at 6:15 PMFennec Pharmaceuticals Inc Forecasted to Post Q4 2024 Earnings of $0.06 Per Share (NASDAQ:FENC)americanbankingnews.com - May 6 at 2:56 AMRosty Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stockamericanbankingnews.com - May 4 at 6:16 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells $22,146.41 in Stockinsidertrades.com - May 3 at 8:03 AMWill Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Knowzacks.com - May 2 at 11:06 AMAdrian Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stockinsidertrades.com - April 23 at 5:00 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Sharesinsidertrades.com - April 23 at 4:22 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $207,118.36 in Stockmarketbeat.com - April 22 at 9:20 PMFennec Pharmaceuticals COO sells shares worth over $536kinvesting.com - April 20 at 11:00 PMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $220,220.02 in Stockinsidertrades.com - April 19 at 6:53 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $228,886.60 in Stockinsidertrades.com - April 18 at 6:32 AMThose who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%finance.yahoo.com - April 9 at 2:14 PMFennec Pharmaceuticals CEO sells shares worth over $950kuk.investing.com - April 7 at 11:51 PMInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells 44,300 Shares of Stockinsidertrades.com - April 6 at 7:31 AMRosty Raykov Sells 40,584 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stockinsidertrades.com - April 5 at 5:10 AMBuy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlookmarkets.businessinsider.com - April 4 at 5:55 PMFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $23,190.58 in Stockinsidertrades.com - March 28 at 8:47 AMChief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)finance.yahoo.com - March 27 at 7:33 PMFennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Sells $153,725.00 in Stockinsidertrades.com - March 26 at 4:44 AMChief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC)finance.yahoo.com - March 26 at 3:23 AMBuy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion Potentialmarkets.businessinsider.com - March 22 at 8:46 AMQ4 2023 Fennec Pharmaceuticals Inc Earnings Callfinance.yahoo.com - March 22 at 8:46 AMFENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 21 at 3:03 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.DermTechNASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.